CYT-0851 / Cyteir Therap - LARVOL DELTA

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=169 | Completed | Sponsor: Cyteir Therapeutics, Inc. | Active, not recruiting ➔ Completed | Trial completion date: Apr 2025 ➔ Dec 2024

Trial completion • Trial completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Breast Cancer • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Head and Neck Cancer • Hematological Malignancies • Hepatology • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Sarcoma • Small Cell Lung Cancer • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • BCL2 • ER • MYC • PGR

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=170 | Active, not recruiting | Sponsor: Cyteir Therapeutics, Inc. | Trial completion date: Dec 2024 ➔ Apr 2025 | Trial primary completion date: Jul 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Breast Cancer • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastrointestinal Cancer • Head and Neck Cancer • Hematological Malignancies • Hepatology • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Sarcoma • Small Cell Lung Cancer • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • BCL2 • ER • MYC • PGR

Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile (Businesswire) - P1/2 | N=170 | NCT03997968 | Sponsor: Cyteir Therapeutics, Inc. | "Cyteir Therapeutics...presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant ovarian cancer in a late-breaker poster...at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting in Boston, Massachusetts....As of the September 26, 2023 data cutoff, 11 patients with advanced ovarian cancer were treated and evaluable in the capecitabine cohort....Two patients had a confirmed partial response by RECIST and one additional patient achieved an unconfirmed partial response. Seven patients had stable disease and one patient had progressive disease. The disease control rate was 91% and median progression-free survival was 170 days."

Late-breaking abstract • P1 data • Ovarian Cancer

Phase 1 dose expansion results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) in platinum-resistant ovarian cancer (AACR-NCI-EORTC 2023) - No abstract available

Combination therapy • Late-breaking abstract • P1 data • Oncology • Ovarian Cancer • Solid Tumor

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=170 | Active, not recruiting | Sponsor: Cyteir Therapeutics, Inc. | Recruiting ➔ Active, not recruiting | N=320 ➔ 170 | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Feb 2023 ➔ Jul 2024

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Breast Cancer • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastrointestinal Cancer • Head and Neck Cancer • Hematological Malignancies • Hepatology • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Sarcoma • Small Cell Lung Cancer • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • BCL2 • ER • MYC • PGR

Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution (Businesswire) - "Cyteir Therapeutics, Inc...announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor, and that Cyteir’s Board of Directors has determined, after consideration of potential strategic alternatives, it is in the best interests of its shareholders to dissolve Cyteir, liquidate its assets following an orderly wind down of the Company’s operations, and return remaining cash to shareholders. CYT-0851 was being evaluated in a Phase 1 combination study with capecitabine or gemcitabine in advanced ovarian cancer and other solid tumors....The Company will continue to treat patients currently enrolled in the Company’s Phase 1 combination study with capecitabine or gemcitabine prior to the effectiveness of the Company’s dissolution."

Discontinued • Breast Cancer • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastrointestinal Cancer • Gynecologic Cancers • Head and Neck Cancer • Hematological Malignancies • Leukemia • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Sarcoma • Small Cell Lung Cancer • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors. (ASCO 2023) - P1/2 | "400 mg QD was selected as the RP2D in combination with cape as no MTD was identified. Escalation of gem + CYT-0851 is ongoing to identify the MTD. Both combinations have demonstrated an acceptable safety and tolerability profile with no unanticipated toxicities at clinically active doses."

Combination therapy • Metastases • P1 data • Anemia • Dermatology • Fatigue • Head and Neck Cancer • Hematological Disorders • Hematological Malignancies • Lymphoma • Mucositis • Neutropenia • Oncology • Ovarian Cancer • Pruritus • Sarcoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Thrombocytopenia

Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile (Businesswire) - P1/2 | N=320 | NCT03997968 | Sponsor: Cyteir Therapeutics, Inc. | "Cyteir Therapeutics...presented results from a Phase 1 study with CYT-0851 in combination with capecitabine or gemcitabine in a poster...at the 2023...ASCO annual meeting....Combination of CYT-0851 with capecitabine:...There was one partial response in an ovarian cancer patient with treatment ongoing in cycle 12 and nine patients had stable disease (five pancreatic cancer patients and four ovarian cancer patients); The overall disease control rate in the capecitabine combination was 71.4%. Combination of CYT-0851 with gemcitabine: Five sarcoma patients, two pancreatic cancer patients and one ovarian cancer patient were response evaluable; There was one confirmed partial response in a sarcoma patient at month two and six patients with stable disease (three sarcoma patients, two pancreatic patients and one ovarian cancer patient). The overall disease control rate was 87.5%."

P1 data • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Pancreatic Cancer • Sarcoma • Solid Tumor

Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights (Businesswire) - "A poster of preliminary results of monotherapy and combination data with CYT-0851 will be presented at the American Society of Clinical Oncology during the Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology poster session on June 3, 2023 at 8:00am."

P1 data • Oncology • Solid Tumor

Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights (Businesswire) - "Cyteir intends to pursue development and potential registration of CYT-0851 in combination with capecitabine as an all-oral treatment for platinum resistant ovarian cancer. Preliminary data on the combination with capecitabine are expected to be disclosed in mid-2023...Preliminary data from the Phase 1 dose escalation cohorts of CYT-0851 in combination with gemcitabine are expected to be disclosed in mid-2023."

P1 data • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway (Businesswire) - "Cyteir Therapeutics...announced the strategic prioritization of clinical development of CYT-0851...as a potential combination therapy for the treatment of ovarian cancer...In the first quarter of 2023, Cyteir expects to determine a maximum tolerated dose ('MTD') for CYT-0851 in combination with capecitabine and focus its efforts on enrolling and treating additional patients with advanced ovarian cancer at the MTD. If the data from these additional patients further support Cyteir’s focus on ovarian cancer, Cyteir intends to pursue development and potential registration of CYT-0851 in combination with capecitabine as an all-oral treatment for platinum resistant ovarian cancer....Enrollment in the Phase 2 monotherapy cohorts with CYT-0851 will be suspended due to insufficient monotherapy activity observed to date. Cyteir plans to disclose the Phase 1 combination data for CYT-0851 in mid-2023."

P1 data • Trial status • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

"$CYT Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway https://t.co/gAK4XQB9LS" (@stock_titan)

Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights (Businesswire) - "Enrollment in the first stage of the Phase 2 solid tumor monotherapy cohorts in sarcoma, pancreatic and ovarian cancer recently completed. Initial data from these cohorts are now expected in the first quarter of 2023. The triple-negative breast cancer monotherapy Phase 2 cohort...continues to enroll with initial data expected in the first half of 2023....Enrollment in the monotherapy Phase 2 cohorts in diffuse large B-cell lymphoma and follicular lymphoma has been delayed due to competition in the treatment landscape. Initial data are now expected in mid-2023. Enrollment in the Phase 1 dose-escalation cohorts of CYT-0851 in combination with capecitabine or gemcitabine is progressing as expected. Completion of enrollment in the capecitabine dose escalation cohorts is anticipated by year-end 2022. Completion of enrollment in the gemcitabine dose escalation cohorts [and] Initial safety and efficacy data from these cohorts are expected in the first half of 2023."

P2 data • Trial status • Breast Cancer • Diffuse Large B Cell Lymphoma • Gastrointestinal Cancer • Gynecologic Cancers • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Sarcoma • Solid Tumor • Triple Negative Breast Cancer

Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers. (ASCO 2022) - P1/2 | "CYT-0851 has demonstrated promising and broad clinical activity in a Ph 1 population of pts with advanced cancers. The safety profile is favorable as characterized by events that were infrequent, primarily Gr1/2, and reversible. Six expansion cohorts (DLBCL, Follicular Lymphoma, Myeloma, Pancreatic, Ovarian and Sarcoma) are enrolling to characterize activity at the RP2D."

Clinical • P1/2 data • Alopecia • Anorexia • Constipation • Dental Disorders • Diffuse Large B Cell Lymphoma • Fatigue • Follicular Lymphoma • Gastroenterology • Gastrointestinal Disorder • Head and Neck Cancer • Hematological Disorders • Hematological Malignancies • Immunology • Lung Cancer • Lymphoma • Metabolic Disorders • Multiple Myeloma • Musculoskeletal Pain • Neuroendocrine Tumor • Non-Hodgkin’s Lymphoma • Oncology • Pain • Sarcoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Stomatitis • RAD51

Identification of the mechanism of action of CYT-0851, an inhibitor of monocarboxylate transporter (MCT) mediated lactate transport (AACR-NCI-EORTC 2022) - "Rapidly proliferating cancers rely on lactate-producing glycolysis which necessitates lactate export through MCTs. CYT-0851 inhibition of MCT-mediated lactate transport in glycolytic cancer cells results in intracellular lactate accumulation, disruption of cellular metabolism and energetics, and cytotoxicity. Given the highly glycolytic nature of many cancers, MCTs are an attractive target for cancer therapies."

Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • MCT1

Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium (Businesswire) - "Cyteir Therapeutics, Inc...announced that the company will be presenting a poster on the mechanism of action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium at the poster session 'Molecular Targeted Agents 1' on Wednesday, October 26, 2022 (Abstract No. 71). Cyteir shared preliminary evidence that CYT-0851 targeted monocarboxylate transporter (MCT) activity at an R&D Day in April 2022 and will provide additional mechanistic data on CYT-0851 at this symposium poster presentation....CYT-0851 is in a Phase 1/2 clinical trial as both a monotherapy and in combination with standard of care chemotherapy and has the potential to be a first-in-class MCT inhibitor. Translational analysis of patient samples is ongoing to confirm pharmacodynamic effects and to identify potential patient selection biomarkers."

Clinical data • Trial status • Breast Cancer • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastrointestinal Cancer • Gynecologic Cancers • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Sarcoma • Small Cell Lung Cancer • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights (Businesswire) - "A Phase 2 cohort with CYT-0851 monotherapy in triple negative breast cancer has been opened. Data from this cohort are expected in the first half of 2023."

P2 data • Breast Cancer • Oncology

CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies (Businesswire) - "Cyteir continues to make progress advancing CYT-0851 in monotherapy and combination clinical studies. Enrollment is ongoing in six disease-specific Phase 2 expansion cohorts with monotherapy in hematologic malignancies and solid tumors. Completion of enrollment in stage 1 of this study is expected before the end of 2022. Enrollment is also ongoing in a Phase 1 combination study of CYT-0851 with three standard-of-care regimens: (1) rituximab plus bendamustine; (2) gemcitabine; and (3) capecitabine, in both hematologic malignancies and solid tumors. Initial safety data from this combination study is expected before the end of 2022."

Enrollment status • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies (Businesswire) - P1 | N=320 | NCT03997968 | Sponsor: Cyteir Therapeutics, Inc | "Cyteir Therapeutics, Inc...presented results from a Phase 1 dose escalation monotherapy trial with CYT-0851 in a poster titled 'Phase 1 Results of CYT-0851 in Patients with Advanced Solid and Hematologic Cancers' (Abstract: 3084, Poster: 76) at the 2022 American Society of Clinical Oncology (ASCO) annual meeting...In solid tumors:...Forty-five patients were response evaluable and one unconfirmed partial response (PR) was achieved in a patient with soft-tissue sarcoma who was treated for almost 11 months; In hematologic cancers:...Eighteen patients with non-Hodgkin lymphoma were response evaluable; To date, CYT-0851 has exhibited a generally well tolerated safety profile with 42% of patients reporting no treatment related adverse events (TRAEs)"

P1 data • Breast Cancer • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hairy Cell Leukemia • Head and Neck Cancer • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

[VIRTUAL] First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers. (ASCO 2021) - P1/2 | "CYT-0851, a first-in-class inhibitor of RAD51-mediated HR, is well tolerated, with linear PK, target-directed PD effects and promising antitumor activity across different tumor types . CYT-0851 is the first DNA-damage repair (DDR) therapeutic with demonstrated clinical activity in both hematologic malignancies and solid tumors . Dose escalation continues to establish the RP2D, with planned expansion in 7 disease-specific cohorts in hematologic and solid cancers."

Clinical • P1/2 data • Constipation • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatology • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pancreatic Cancer • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • CTCs • RAD51

Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights (Businesswire) - "2022 Expected Key Milestones...: (i) Present data from Phase 1 CYT-0851 monotherapy dose escalation study; (ii) Announce top line safety data from Phase 1 CYT-0851 combination therapy study; (iii) Announce top line interim results from stage 1 of CYT-0851 Phase 2 monotherapy study; (iv) Design potential registrational trial for one or more indications with CYT-0851; (v) File IND for CYT-1853."

IND • New trial • P1 data • P2 data • Hematological Malignancies • Oncology • Solid Tumor

A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=320 | Recruiting | Sponsor: Cyteir Therapeutics, Inc. | Trial completion date: Oct 2022 ➔ Dec 2023 | Trial primary completion date: Sep 2021 ➔ Feb 2023

Trial completion date • Trial primary completion date • Breast Cancer • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastrointestinal Cancer • Head and Neck Cancer • Hematological Malignancies • Hepatology • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Sarcoma • Small Cell Lung Cancer • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • BCL2 • ER • HER-2 • MYC • PGR

Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851 (Businesswire) - "Cyteir Therapeutics...announced that the first patient has been dosed in a Phase 2 expansion cohort study of CYT-0851 monotherapy that is part of the Phase 1/2 trial. CYT-0851 is being evaluated for the treatment of hematologic malignancies and solid tumors....For the Phase 2 monotherapy expansion cohort study with CYT-0851 (NCT Number NCT03997968), we intend to enroll in six disease-specific cohorts in hematologic malignancies (relapsed and/or refractory diffuse large B-cell lymphoma, follicular lymphoma, and multiple myeloma) and solid tumors (recurrent metastatic or locally advanced pancreatic cancer, progressive ovarian cancer, and metastatic soft tissue sarcoma)."

Trial status • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastrointestinal Cancer • Gynecologic Cancers • Hematological Malignancies • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial With CYT-0851 (Businesswire) - "Cyteir Therapeutics...announced that the first patient has been dosed in a Phase 1 trial evaluating CYT-0851 in combination with three standard-of-care chemotherapy regimens in both hematologic malignancies and solid tumors....The Phase 1 combination trial with CYT-0851 is with three standard-of-care regimens: rituximab plus bendamustine, gemcitabine, and capecitabine, in both hematologic malignancies and solid tumors (NCT Number NCT03997968). Initial safety data from these combinations is expected by year end."

P1 data • Trial status • Hematological Malignancies • Oncology • Solid Tumor

Cyteir Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights (Businesswire) - P1/2, N=320; NCT03997968; Sponsor: Cyteir Therapeutics, Inc; "Cyteir completed the dose-escalation portion of its Phase 1/2 study of CYT-0851 up to the maximum feasible daily dose of 1200 mg and declared the maximum tolerated dose of 600mg per day. Dose limiting toxicities of fatigue, vomiting, dehydration, dry skin, stomatitis, myalgia, and acidosis were observed at daily doses of 600mg and above...We continue to enroll patients at the 400mg per day dose....we are initiating Phase 2 expansion study into disease-specific cohorts and expect to begin enrolling patients in the first quarter of 2022. We are also initiating a Phase 1 combination study of CYT-0851 with three standard-of-care regimens: rituximab plus bendamustine, gemcitabine and capecitabine, in both hematologic malignancies and solid tumors; Investigational New Drug (IND)-enabling studies with CYT-1853 are ongoing and the Company expects to submit an IND application for CYT-1853 in 2022."

Enrollment status • IND • New P1 trial • New P2 trial • P1/2 data • Breast Cancer • Gynecologic Cancers • Head and Neck Cancer • Hematological Malignancies • Leukemia • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Triple Negative Breast Cancer